|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Phase Forward (PFWD), a leading provider of integrated data management software for clinical trials and drug safety. |
|---|---|
| Transferring Party | Lincoln Technologies, a provider of products and services for strategic pharmacovigilance, clinical trial safety signal detection, and applied data standards. |
| Sector | Data Management/ Healthcare IT |
| Date | August 16, 2005 |
| Analysis In this all-cash Deal valued at $11 million (plus up to an additional $6 million in milestone payments), Phase Forward adds regulatory expertise and drug safety information technologies to its product line. Lincoln's revenues are about $4.5mm and it's profitable. Lincoln adds major new customers to Phase Forward -- Department of Defense and NIH; there are several customers currently served by both. The agreement is subject to several conditions. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |